Bausch Health Companies Inc - Company Profile
Powered by 
All the data and insights you need on Bausch Health Companies Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Bausch Health Companies Inc Strategy Report
- Understand Bausch Health Companies Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Bausch Health Companies Inc (Bausch Health), formerly Valeant Pharmaceuticals International Inc, is engaged in the manufacturing, development, and marketing of a range of medical devices, over-the-counter products (OTC), and pharmaceutical products. Bausch Health offers products for therapy areas related to dermatology, gastroenterology, eye health, neurology, aesthetic devices, dentistry, and consumer health. It offers various generic and branded generic products. Bausch Health has administrative, research and laboratory, marketing, distribution, and warehousing facilities worldwide. The company offers products directly or indirectly in various regions across the world including the US, Canada, Africa, Middle East, Australia, Latin America, and Europe. It also operates manufacturing facilities in the US, Brazil, Columbia, Germany, Canada, among others. Bausch Health is headquartered in Laval, Quebec, Canada.
Headquarters
Canada
Address
2150 Saint-Elzear Blvd W, Laval, Quebec, H7L4A8
Website
www.bauschhealth.com
Telephone
1 514 7446792
No of Employees
20,270
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BHC (TSE)
Revenue (2022)
$8.8B
7.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-163.1%
(2022 vs 2021)
Market Cap*
$3.2B
Net Profit Margin (2022)
XYZ
-144.0%
(2022 vs 2021)
* As of and is in US$
Bausch Health Companies Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Dermatological | - |
| Actinic keratosis | Aergel |
| Acne | Akreos |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Litigation | In April, the company and Salix Pharmaceuticals filed a lawsuit against Amneal Pharmaceuticals of New York, LLC, Amneal EU, Limited, Amneal Pharmaceuticals, LLC, Amneal Pharmaceuticals Private Limited, and Amneal Pharmaceuticals, Inc. over a generic version of XIFAXAN. |
| 2024 | New Products/Services | In January, the company launched CABTREO (clindamycin, adapalene, benzoyl peroxide) Topical Gel, 1.2%/0.15%/3.1% in the US. |
| 2023 | Contracts/Agreements | In December, Salix Pharmaceuticals joined forces with The International Foundation for Gastrointestinal Disorders to declare Opioid-Induced Constipation (OIC) Awareness Day. |
Competitor Comparison
| Key Parameters | Bausch Health Companies Inc | Eli Lilly and Co | Amgen Inc | Teva Pharmaceutical Industries Ltd | Viatris Inc |
|---|---|---|---|---|---|
| Headquarters | Canada | United States of America | United States of America | Israel | United States of America |
| City | Laval | Indianapolis | Thousand Oaks | Tel Aviv | Canonsburg |
| State/Province | Quebec | Indiana | California | Tel Aviv | Pennsylvania |
| No. of Employees | 20,270 | 43,000 | 26,700 | 35,001 | 38,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Thomas J. Appio | Chief Executive Officer | Senior Management | 2022 | 61 |
| Mirza Dautbegovic | Chief Operating Officer; Senior Vice President | Senior Management | 2022 | - |
| Tage Ramakrishna, M.D. | President - R&D; Chief Medical Officer | Senior Management | - | - |
| Kathleen Fitzpatrick | Senior Vice President; Chief Human Resources Officer | Senior Management | 2022 | - |
| Graham Jackson | Senior Vice President; Chief Quality Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward